Cerity Partners LLC Boosts Position in Guardant Health, Inc. (NASDAQ:GH)

Cerity Partners LLC increased its holdings in Guardant Health, Inc. (NASDAQ:GH) by 54.6% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 195,008 shares of the company’s stock after acquiring an additional 68,883 shares during the quarter. Cerity Partners LLC owned about 0.16% of Guardant Health worth $4,473,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also added to or reduced their stakes in the company. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Guardant Health by 21.8% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,449 shares of the company’s stock worth $102,000 after acquiring an additional 796 shares during the period. JNBA Financial Advisors purchased a new stake in Guardant Health in the third quarter worth $26,000. Ashton Thomas Securities LLC bought a new position in Guardant Health in the third quarter worth $34,000. Quarry LP purchased a new position in Guardant Health during the second quarter valued at $44,000. Finally, Green Alpha Advisors LLC boosted its holdings in shares of Guardant Health by 23.6% during the 3rd quarter. Green Alpha Advisors LLC now owns 8,782 shares of the company’s stock valued at $201,000 after buying an additional 1,674 shares in the last quarter. Institutional investors own 92.60% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on GH shares. The Goldman Sachs Group increased their price target on shares of Guardant Health from $32.00 to $36.00 and gave the stock a “buy” rating in a research note on Thursday, November 7th. Leerink Partners dropped their price target on Guardant Health from $60.00 to $50.00 and set an “outperform” rating on the stock in a research report on Thursday, October 17th. Craig Hallum raised their price objective on Guardant Health from $28.00 to $37.00 and gave the company a “buy” rating in a research report on Thursday, August 8th. JPMorgan Chase & Co. boosted their target price on Guardant Health from $48.00 to $50.00 and gave the stock an “overweight” rating in a report on Thursday, November 7th. Finally, Piper Sandler raised their price target on Guardant Health from $30.00 to $34.00 and gave the company an “overweight” rating in a report on Tuesday, August 13th. One analyst has rated the stock with a hold rating and fifteen have given a buy rating to the company. According to data from MarketBeat.com, Guardant Health presently has a consensus rating of “Moderate Buy” and an average target price of $40.60.

Insiders Place Their Bets

In other news, Director Meghan V. Joyce sold 2,896 shares of Guardant Health stock in a transaction dated Wednesday, November 13th. The stock was sold at an average price of $29.90, for a total transaction of $86,590.40. Following the transaction, the director now directly owns 7,648 shares of the company’s stock, valued at $228,675.20. The trade was a 27.47 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 5.50% of the company’s stock.

Guardant Health Trading Up 2.1 %

NASDAQ:GH opened at $35.10 on Friday. The company has a market cap of $4.34 billion, a PE ratio of -8.28 and a beta of 1.11. The company has a current ratio of 6.22, a quick ratio of 5.85 and a debt-to-equity ratio of 16.70. The company has a 50 day simple moving average of $24.81 and a two-hundred day simple moving average of $27.20. Guardant Health, Inc. has a 12 month low of $15.81 and a 12 month high of $37.04.

Guardant Health (NASDAQ:GH) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($0.88) EPS for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.33). The firm had revenue of $191.48 million for the quarter, compared to analysts’ expectations of $170.49 million. Guardant Health had a negative net margin of 74.02% and a negative return on equity of 1,200.44%. The firm’s revenue was up 33.9% compared to the same quarter last year. During the same quarter last year, the company posted ($0.73) EPS. Research analysts forecast that Guardant Health, Inc. will post -3.38 earnings per share for the current year.

Guardant Health Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.